

CITATION REPORT

List of articles citing

Maintaining consistent quality and clinical performance of biopharmaceuticals

DOI: 10.1080/14712598.2018.1421169

Expert Opinion on Biological Therapy, 2018, 18, 369-379.

Source: <https://exaly.com/paper-pdf/69230302/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	Introductory Chapter: Biopharmaceuticals. 2018 ,		4
33	Drug Product Considerations for Biosimilars. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2018 , 221-258	0.5	
32	Totality of Evidence and the Role of Clinical Studies in Establishing Biosimilarity. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2018 , 601-628	0.5	3
31	An Efficient Development Paradigm for Biosimilars. <i>BioDrugs</i> , 2019 , 33, 603-611	7.9	15
30	Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 102785	7	2
29	Biosimilar and interchangeable: Inseparable scientific concepts?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2460-2463	3.8	9
28	Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis. <i>MAbs</i> , 2019 , 11, 1452-1463	6.6	3
27	Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?. <i>BioDrugs</i> , 2019 , 33, 437-446	7.9	8
26	Toward Real Time IoT Based Paste Monitoring System for Small to Medium Enterprise (SME). <i>Journal of Physics: Conference Series</i> , 2019 , 1167, 012006	0.3	1
25	Current state of biologic pharmacovigilance in the European Union: improvements are needed. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 231-240	4.1	9
24	Isothermal titration calorimetry for characterization of recombinant proteins. <i>Current Opinion in Biotechnology</i> , 2019 , 55, 9-15	11.4	17
23	The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. <i>MAbs</i> , 2019 , 11, 13-25	6.6	9
22	Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020 , 20, 653-659	2.2	4
21	The first World Health Organization International Standard for in vitro biological activity of darbepoetin. <i>Biologicals</i> , 2020 , 63, 33-38	1.8	1
20	Glycan analysis of erythropoiesis-stimulating agents. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 180, 113031	3.5	2
19	The Importance of Countering Biosimilar Disparagement and Misinformation. <i>BioDrugs</i> , 2020 , 34, 407-414	7.9	13
18	Degradable High Molecular Weight Monodisperse Dendritic Poly(ethylene glycols). <i>Biomacromolecules</i> , 2020 , 21, 4294-4301	6.9	2

17	Adipose-Derived Biogenic Nanoparticles for Suppression of Inflammation. <i>Small</i> , 2020 , 16, e1904064	11	22
16	Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. <i>BioDrugs</i> , 2020 , 34, 225-233	7.9	4
15	Maintaining Standards for biosimilar monoclonal antibodies. <i>Nature Biotechnology</i> , 2021 , 39, 276-280	44.5	5
14	The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. <i>Advances in Therapy</i> , 2021 , 38, 2077-2093	4.1	4
13	The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. <i>Frontiers in Immunology</i> , 2021 , 12, 636420	8.4	1
12	Availability, affordability and drug utilization of biosimilar medicinal products, containing monoclonal antibodies in Bulgaria. <i>Journal of Generic Medicines</i> , 174113432110176	0.2	3
11	Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. <i>BioDrugs</i> , 2021 , 35, 379-387	7.9	1
10	Extrapolation: Experience gained from original biologics. <i>Drug Discovery Today</i> , 2021 , 26, 2003-2013	8.8	3
9	Recent biopharmaceutical applications of capillary electrophoresis methods on recombinant DNA technology-based products. <i>Electrophoresis</i> , 2021 ,	3.6	0
8	Coupling of Trastuzumab chromatographic profiling with machine learning tools: A complementary approach for biosimilarity and stability assessment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1184, 122976	3.2	1
7	Assurance of quality, safety and efficacy of vaccines through compliance of quality management processes. <i>Journal of Analytical & Pharmaceutical Research</i> , 2019 , 8, 188-191	0.4	
6	Nature and timing of post-approval manufacturing changes of tumour necrosis factor inhibitor products: A 20-year follow-up study of originators and biosimilars. <i>European Journal of Pharmaceutical Sciences</i> , 2022 , 175, 106227	5.1	
5	Divergent Synthesis of Biocompatible Nearly Monodisperse Multi-Functional Poly(ethylene glycol) Periodic Copolymers. <i>Macromolecular Chemistry and Physics</i> , 2200109	2.6	
4	The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.		1
3	Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study. 1-8		0
2	Variability of Biologics and its Impact on Biosimilar Development. 22-30		0
1	Consistency of Product Quality for SB5, an Adalimumab Biosimilar.		0